Key Points
- Meredith Cook sold 500 shares of ANI Pharmaceuticals on January 13 at an average price of $84.33 for $42,165, trimming her holdings by 0.67% to 74,374 shares.
- ANI reported a strong quarter on November 7, with EPS of $2.04 beating estimates ($1.74) and revenue of $227.8M (vs. $211.9M), and set FY2025 guidance of 7.370–7.640 EPS.
- Analyst sentiment is broadly positive—six Buys and three Holds—with a consensus target of $102.14 and several firms raising targets (e.g., JPMorgan to $115, HC Wainwright to $121; Barclays coverage with a $100 target).
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the company's stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the transaction, the vice president directly owned 74,374 shares of the company's stock, valued at $6,271,959.42. The trade was a 0.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Meredith Cook also recently made the following trade(s):
- On Friday, December 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $82.32, for a total value of $32,928.00.
- On Thursday, November 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $87.27, for a total transaction of $34,908.00.
ANI Pharmaceuticals Stock Up 3.3%
ANIP opened at $85.03 on Thursday. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50. The company has a market cap of $1.91 billion, a PE ratio of 52.17 and a beta of 0.51. The company has a 50-day moving average price of $82.22 and a 200 day moving average price of $83.55.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The business had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same quarter last year, the business posted $1.34 earnings per share. The business's quarterly revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ANI Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in ANI Pharmaceuticals by 321.0% during the 4th quarter. SG Americas Securities LLC now owns 96,181 shares of the specialty pharmaceutical company's stock worth $7,593,000 after buying an additional 73,334 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in ANI Pharmaceuticals by 93.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 89,777 shares of the specialty pharmaceutical company's stock worth $7,087,000 after purchasing an additional 43,449 shares during the last quarter. Oliver Luxxe Assets LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $1,823,000. Tudor Investment Corp ET AL acquired a new position in ANI Pharmaceuticals in the third quarter valued at approximately $1,085,000. Finally, Penn Capital Management Company LLC increased its stake in ANI Pharmaceuticals by 6.5% in the third quarter. Penn Capital Management Company LLC now owns 6,364 shares of the specialty pharmaceutical company's stock valued at $583,000 after purchasing an additional 387 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on ANIP. JPMorgan Chase & Co. raised their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 24th. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a "hold" rating in a research report on Thursday, October 9th. HC Wainwright boosted their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Weiss Ratings reissued a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Finally, Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 price objective for the company. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $102.14.
View Our Latest Stock Report on ANIP
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
